Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be live webcast and accessible on the company's website. A replay will also be available for at least 30 days.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34^th Annual Healthcare Life Sciences Conference on February 13, 2024 at 11:20 a.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206410430/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

Enanta Pharmaceuticals will participate in the conference on February 13, 2024.

Who will be participating in the fireside chat at the conference?

The President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in the fireside chat.

Where can the live webcast of the event be accessed?

The live webcast of the event will be accessible on Enanta's website under the 'Events and Presentations' section on the 'Investors' page.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available following the presentation and will be archived for at least 30 days.